Research progress in anti-AIDS compound preparations

doi:10.19803/j.1672-8629.20240275

Abstract

Abstract: Objective To outline the principles and requirements of developing compound preparations against acquired immunodeficiency syndrome (AIDS), and summarize the simplified regimens of antiretroviral therapy (ART) so as to provide references for seeking the best drug therapy regimens. Methods By searching related domestic and foreign literature and databases, the compound preparations against AIDS on the market were sorted out and analyzed. Results The currently marketed compound preparations against AIDS could simplify ART regimens, enhance medication compliance, reduce drug side effects, lower the drug burden, and improve patients' quality of life. Conclusion Compound preparations against AIDS have significant advantages therapeutically, but there are still significant clinical needs for the treatment of and drug development for this disease, which requires more in-depth research.

Key words: human immunodeficiency virus, acquired immune deficiency syndrome (AIDS), combination drug, compound preparation, drug development

CLC Number:

R916
R978

SUN Siman, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, WANG Chuan, JIN Hongtao. Research progress in anti-AIDS compound preparations[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 978-984.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240275

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/978

References

[1] HE YZ, CHEN XT, CHEN JL, et al.Changes and progress of AIDS antiviral therapy drugs in China[J]. Guangdong Medical Journal(广东医学), 2023, 44(2): 157-160.
[2] OH KS, SEO GH, CHOI HK, et al.Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea[J]. Sci Rep, 2022, 12(1): 2031.
[3] TANG LL, HUANG HP.Impurity control for compound preparation and its impact on product optimization[J]. Modern Chemical Research(当代化工研究), 2023(19): 188-190
[4] CHEN GL, ZHANG L, CHEN P, et al.The status and prospect of research and development of drug combinations[J]. Chinese Journal of New Drugs(中国新药杂志), 2016, 25(19): 2205-2210.
[5] FOKA FET, MUFHANDU HT.Current ARTs, virologic failure, and implications for AIDS management: a systematic review[J]. Viruses, 2023, 15(8): 1732.
[6] CAO XJ, CAO J, QI H, et al.HIV-1 primary drug resistance at home and abroad[J]. Journal of Modern Medicine & Health(现代医药卫生), 2022, 38(24): 4226-4230.
[7] Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center For Disease Control and Prevention. Chinese AIDS diagnosis and treatment guidelines (2024 Edition)[Z]. Chinese Journal of Infectious Diseases(中华传染病杂志), 2024.
[8] FU ZP, KANG DW, LIU XY, et al.New progress of target-based anti-AIDS drugs[J]. Progress in Pharmaceutical Sciences(药学进展), 2020, 44(9): 681-697.
[9] AMBLARD F, PATEL D, MICHAILIDIS E, et al.HIV nucleoside reverse transcriptase inhibitors[J]. Eur J Med Chem, 2022, 240: 114554.
[10] GULICK RM, RIBAUDO HJ, SHIKUMA CM, et al.Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection[J]. N Engl J Med, 2004, 350(18): 1850-1861.
[11] ZHU YJ, MEI PF, XU QQ, et al.Quantitative study of HIV-1 RNA in plasma and HIV-1 DNA in cells of patients treated with highly effective antiviral therapy[J]. Chinese Preventive Medicine(中国预防医学杂志), 2022, 23(3): 167-170.
[12] EDWARDS Z, INGOLD CJ, AZMAT CE.Zidovudine[M]. Treasure Island: StatPearls Publishing LLC, 2024.
[13] MA HL, LI JW, LIU A, et al.Clinical observation of antiviral treatment of HIV based on zidovudine and lamivudine tablets[J]. Chinese Journal of AIDS & STD(中国艾滋病性病), 2016, 22(8): 605-607.
[14] PORTSMOUTH SD, SCOTT CJ.The renaissance of fixed dose combinations: Combivir[J]. Ther Clin Risk Manag, 2007, 3(4): 579-583.
[15] HUANG WY, GUO SY, ZHANG XD.Clinical efficacy, medicinal mechanism and adverse reactions of classical and novel AIDS antiviral drugs[J]. China Journal of Pharmaceutical Economics(中国药物经济学), 2022, 17(1): 51-55.
[16] ASTUTI N, MAGGIOLO F.Single-tablet regimens in HIV therapy[J]. Infect Dis Ther, 2014, 3(1): 11-17.
[17] DEEKS ED, PERRY CM.Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla^®): a review of its use in the management of HIV infection[J]. Drugs, 2010, 70(17): 2315-2338.
[18] DEJESUS E, YOUNG B, MORALES-RAMIREZ JO, et al.Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients[J]. J Acquir Immune Defic Syndr, 2009, 51(2): 163-174.
[19] MUCCINI C, CASTAGNA A.A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults[J]. Expert Rev Anti Infect Ther, 2023, 21(11): 1167-1176.
[20] DEEKS ED.Darunavir: a review of its use in the management of HIV-1 infection[J]. Drugs, 2014, 74(1): 99-125.
[21] JIANG TY, LI B, WANG W, et al.Research progress of darunavir in treatment of HIV infection[J]. Chinese Journal of AIDS & STD(中国艾滋病性病), 2020, 26(7): 783-786, 790.
[22] ERON JJ, ORKIN C, GALLANT J, et al.A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients[J]. Aids, 2018, 32(11): 1431-1442.
[23] SCARSI KK, HAVENS JP, PODANY AT, et al.HIV-1 Integrase inhibitors: a comparative review of efficacy and safety[J]. Drugs, 2020, 80(16): 1649-1676.
[24] SCOTT L J.Dolutegravir/Lamivudine single-tablet regimen: a review in HIV-1 infection[J]. Drugs, 2020, 80(1): 61-72.
[25] DE CLERCQ E, ZHANG Z, HUANG J, et al.Biktarvy for the treatment of HIV infection: progress and prospects[J]. Biochem Pharmacol, 2023, 217: 115862.
[26] BAI J, ZHANG C.Application and research progress of Bienpranol in the treatment of acquired immune deficiency syndrome[J]. Clinical Medication Journal(临床药物治疗杂志), 2021, 19(3): 20-25.
[27] CENTO V, PERNO CF.Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety[J]. J Glob Antimicrob Resist, 2020, 20: 228-237.
[28] LLIBRE JM, HUNG CC, BRINSON C, et al.Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies[J]. Lancet, 2018, 391(10123): 839-849.
[29] RHEE SY, KASSAYE SG, BARROW G, et al.HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates[J]. J Int AIDS Soc, 2020, 23(9): e25611.
[30] MOHAMED H, GURROLA T, BERMAN R, et al.Targeting CCR5 as a component of an HIV-1 therapeutic strategy[J]. Front Immunol, 2021, 12: 816515.
[31] NAKATA H, MAEDA K, DAS D, et al.Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s[J]. Sci Rep, 2019, 9(1): 4828.
[32] HEREDIA A, LATINOVIC O, GALLO RC, et al.Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1[J]. Proc Natl Acad Sci USA, 2008, 105(51): 20476-20481.
[33] FAIVRE N, VEROLLET C, DUMAS F.The chemokine receptor CCR5: multi-faceted hook for HIV-1[J]. Retrovirology, 2024, 21(1): 2.
[34] GULICK RM, SU Z, FLEXNER C, et al.Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211[J]. J Infect Dis, 2007, 196(2): 304-312.
[35] AIAMKITSUMRIT B, DAMPIER W, MARTIN-GARCIA J, et al.Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences[J]. PLoS One, 2014, 9(9): e107389.
[36] KUFEL WD.Antibody-based strategies in HIV therapy[J]. Int J Antimicrob Agents, 2020, 56(6): 106186.
[37] JACOBSON JM, LALEZARI JP, THOMPSON MA, et al.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults[J]. Antimicrob Agents Chemother, 2010, 54(10): 4137-4142.
[38] ELLWANGER JH, KAMINSKI VL, CHIES JA.What we say and what we mean when we say redundancy and robustness of the chemokine system - how CCR5 challenges these concepts[J]. Immunol Cell Biol, 2020, 98(1): 22-27.
[39] SUN L.Design, synthesis and bioactivity evaluation of novel HIV-1 capsid protein inhibitors and RNase H inhibitors[D]. Jinan: Shandong University, 2021.
[40] SEGAL-MAURER S, DEJESUS E, STELLBRINK HJ, et al.Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection[J]. N Engl J Med, 2022, 386(19): 1793-1803.
[41] GUPTA SK, BERHE M, CROFOOT G, et al.Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial[J]. Lancet HIV, 2023, 10(1): e15-e23.
[42] PAIK J.Lenacapavir: first approval[J]. Drugs, 2022, 82(14): 1499-1504.